Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”

• Jorge A. Gómez,
• Thatiana de Jesus Pereira Pinto,
• Javier Nieto Guevara,
• Tatiana Guimarães de Noronha

Affiliations

Jorge A. Gómez

GlaxoSmithKline

Thatiana de Jesus Pereira Pinto

GlaxoSmithKline

Javier Nieto Guevara

GlaxoSmithKline

Tatiana Guimarães de Noronha

Institute of Technology for Immunobiologicals of Bio-Manguinhos, FIOCRUZ